Effect of Oral Chinese Medicine Decoction on Endpoint Events in Non-dialysis Patients with Stage 3-5 Chronic Kidney Disease： A Retrospective Cohort Study

ZHANG Min; XU Xueyi; FU Lizhe; TANG Fang; JIE Xina; LIU Xusheng; WU Yifan

doi:10.13288/j.11-2166/r.2022.20.008

您当前的位置：

首页 >

文章列表页 >

Effect of Oral Chinese Medicine Decoction on Endpoint Events in Non-dialysis Patients with Stage 3-5 Chronic Kidney Disease： A Retrospective Cohort Study

更新时间：2022-10-13

- Effect of Oral Chinese Medicine Decoction on Endpoint Events in Non-dialysis Patients with Stage 3-5 Chronic Kidney Disease： A Retrospective Cohort Study
- Journal of Traditional Chinese Medicine Vol. 63, Issue 20, Pages: 1936-1945(2022)
- 作者机构：
  
  1.广州中医药大学第二临床医学院，广东省广州市越秀区大德路111号，510120
  2.广东省中医院
- 作者简介：
- 基金信息：
- DOI：10.13288/j.11-2166/r.2022.20.008
  CLC：
- Received：08 February 2022，
  
  Revised：2022-05-30，
  
  Published：17 October 2022
- 稿件说明：
移动端阅览
张敏,许雪仪,傅立哲等.中药汤剂口服治疗对慢性肾脏病3-5期非透析患者终点事件的影响——一项回顾性队列研究[J].中医杂志,2022,63(20):1936-1945.

ZHANG Min,XU Xueyi,FU Lizhe,et al.Effect of Oral Chinese Medicine Decoction on Endpoint Events in Non-dialysis Patients with Stage 3-5 Chronic Kidney Disease： A Retrospective Cohort Study[J].Journal of Traditional Chinese Medicine,2022,63(20):1936-1945.
张敏,许雪仪,傅立哲等.中药汤剂口服治疗对慢性肾脏病3-5期非透析患者终点事件的影响——一项回顾性队列研究[J].中医杂志,2022,63(20):1936-1945. DOI： 10.13288/j.11-2166/r.2022.20.008.

ZHANG Min,XU Xueyi,FU Lizhe,et al.Effect of Oral Chinese Medicine Decoction on Endpoint Events in Non-dialysis Patients with Stage 3-5 Chronic Kidney Disease： A Retrospective Cohort Study[J].Journal of Traditional Chinese Medicine,2022,63(20):1936-1945. DOI： 10.13288/j.11-2166/r.2022.20.008.

摘要

目的

探讨中药汤剂治疗对慢性肾脏病（CKD）3-5期非透析患者终点事件的影响。

方法

回顾性收集2010年3月1日至2019年5月20日在广东省中医院肾病科慢病管理门诊首诊的CKD 3-5期患者的临床资料，根据既往服用中药情况，将患者分为中药汤剂组和非中药汤剂组。收集患者基本信息、实验室指标及发生终点事件（透析或移植，死亡）情况，以2020年12月30日前所能查到的最后一个时点的终点状态为准，若发生终点事件则记录为到达终点。采用倾向性评分匹配的方法平衡基线差异，对匹配前后的队列采用Kaplan-Meier曲线分析比较两组患者累积终点事件发生率，再用单因素和多因素COX回归分析匹配前后患者口服中药汤剂及其他因素对发生终点事件风险的影响。

结果

匹配前中药汤剂组患者728例中185例发生了终点事件，非中药汤剂组患者57例中21例发生了终点事件。匹配后中药汤剂组患者111例中26例发生了终点事件，非中药汤剂组患者56例中21例发生了终点事件。Kaplan-Meier曲线分析结果显示，匹配前后中药汤剂组患者累积终点事件发生率均显著低于非中药汤剂组（

匹配前

=0.029，

匹配后

=0.040）。多因素COX回归分析结果显示，匹配前后与非中药汤剂组比较，中药汤剂组患者发生终点事件的风险均显著降低［HR：0.45，95%

（0.28，0.72），

匹配前

=0.001；HR：0.35，95%

（0.16，0.76），

匹配后

=0.008］。血红蛋白（Hb）、CKD分期、尿蛋白（PRO）亦是发生终点事件风险影响因素（

＜0.05）。

结论

中药汤剂治疗可能有效降低CKD 3-5期患者终点事件发生风险，延缓疾病进展。

Abstract

Objective

To evaluate the effect of Chinese medicine decoction （CMD） on endpoint events in non-dialysis patients with stage 3-5 chronic kidney disease（CKD）.

Methods

Data of patients who had a first visit to the Chronic Disease Management Clinic at the Nephrology Department of the Guangdong Provincial Hospital of Chinese Medicine between March 1st， 2010 and May 20th， 2019 were retrospectively collected， and patients were divided to the CMD group and the non-CMD group according to previous CMD history. The basic information， laboratory indicators and endpoint events （dialysis or transplantation， death） were collected. The endpoint status at the last time point before December 30th， 2020 was recorded， and if an endpoint event occurs， it will be recorded as reaching the endpoint. Propensity score matching （PSM） was used to balance the baseline differences， and Kaplan-Meier curve analysis was used to compare the cumulative endpoint event rates of the two groups before and after matching. Univariate and multivariate COX regression analysis was performed to analyze the influence of oral administration of CMD and other factors on the occurrence of endpoint events before and after PSM.

Results

Before matching， 185 out of 728 cases in the CMD group， and 21 out of 57 cases in the non-CMD group had endpoint events. The proportions changed into 26/111 and 21/56 after matching. Kaplan-Meier curve analysis showed that the incidence rate of cumulative endpoint events in the CMD group was significantly lower than that of non-CMD group either before or after matching （before matching：

= 0.029； after matching：

= 0.040）. Multivariate Cox regression showed that patients in the CMD group had a significantly lower risk of endpoint events compared to those in the non-CMD group either before （HR = 0.45； 95%

： 0.28， 0.72；

= 0.001） or after PSM （HR = 0.35； 95%

： 0.16， 0.76；

= 0.008）. Hemoglobin， CKD stage， and urine protein were also risk factors for the occurrence of endpoint events （

＜0.05）.

Conclusion

Oral administration of CMD might effectively reduce the incidence of endpoint events and delay the disease progression in patients with stages 3-5 CKD .

关键词

Keywords

references

GBD chronic kidney disease collaboration . Global， regio-nal， and national burden of chronic kidney disease， 1990-2017： a systematic analysis for the Global Burden of Disease Study 2017 ［J］. Lancet ， 2020 ， 10225 （ 395 ）： 709 - 733 .

LIYANAGE T ， NINOMIYA T ， JHA V ， et al . Worldwide access to treatment for end-stage kidney disease： a syste-matic review ［J］. Lancet ， 2015 ， 385 （ 9981 ）： 1975 - 1982 .

MARKELL MS . Potential benefits of complementary medicine modalities in patients with chronic kidney disease ［J］. Adv Chronic Kidney Dis ， 2005 ， 12 （ 3 ）： 292 - 299 .

National kidney foundation . K/DOQI clinical practice guidelines for chronic kidney disease： evaluation， classification， and stratification ［J］. Am J Kidney Dis ， 2002 ， 39 （2 Suppl 1 ）： S1 - S266 .

JOHNSON ES ， THORP ML ， YANG X ， et al . Predicting renal replacement therapy and mortality in CKD ［J］. Am J Kidney Dis ， 2007 ， 50 （ 4 ）： 559 - 565 .

WU Y ， LI C ， ZHANG L ， et al . Effectiveness of Chinese herbal medicine combined with Western medicine on deferring dialysis initiation for nondialysis chronic kidney disease stage 5 patients： a multicenter prospective nonrandomized controlled study ［J］. Ann Transl Med ， 2021 ， 9 （ 6 ）： 490 - 508 .

HSIEH CF ， HUANG SL ， CHEN CL ， et al . Non-aristolochic acid prescribed Chinese herbal medicines and the risk of mortality in patients with chronic kidney disease： results from a population-based follow-up study ［J］. BMJ Open ， 2014 ， 4 （ 2 ）： e4033 - e4041 .

LIN MY ， CHIU YW ， CHANG JS ， et al . Association of prescribed Chinese herbal medicine use with risk of end-stage renal disease in patients with chronic kidney disease ［J］. Kidney Int ， 2015 ， 88 （ 6 ）： 1365 - 1373 .

HUANG KC ， SU YC ， SUN MF ， et al . Chinese herbal medicine improves the long-term survival rate of patients with chronic kidney disease in Taiwan： a nationwide re-trospective population-based cohort study ［J］. Front Pharmacol ， 2018 ， 9 （ 3 ）： 1117 - 1127 .

CHEN HY ， PAN HC ， CHEN YC ， et al . Traditional Chinese medicine use is associated with lower end-stage renal disease and mortality rates among patients with diabetic nephropathy： a population-based cohort study ［J］. BMC Complement Altern Med ， 2019 ， 19 （ 1 ）： 81 - 94 .

HOSHINO J ， MUENZ D ， ZEE J ， et al . Associations of Hemoglobin levels with health-related quality of life， physical activity， and clinical outcomes in persons with stage 3-5 nondialysis CKD ［J］. J Ren Nutr ， 2020 ， 30 （ 5 ）： 404 - 414 .

YAMAMOTO T ， MIYAZAKI M ， NAKAYAMA M ， et al . Impact of hemoglobin levels on renal and non-renal clinical outcomes differs by chronic kidney disease stages： the Gonryo study ［J］. Clin Exp Nephrol ， 2016 ， 20 （ 4 ）： 595 - 602 .

JOHNSON ES ， THORP ML ， YANG XM ， et al . Predic-ting renal replacement therapy and mortality in CKD ［J］. Am J Kidney Dis ， 2007 ， 50 （ 4 ）： 559 - 565 .

MARKS A ， FLUCK N ， PRESCOTT GJ ， et al . Definitions of progression in chronic kidney disease：predictors and relationship to renal replacement therapy in a population cohort with a 6 year follow-up ［J］. Nephrol Dial Transplant ， 2014 ， 29 （ 2 ）： 333 - 341 .

METHVEN S ， MACGREGOR MS ， TRAYNOR JP ， et al . Comparison of urinary albumin and urinary total protein as predictors of patient outcomes in CKD ［J］. Am J Kidney Dis ， 2011 ， 57 （ 1 ）： 21 - 28 .

陈英兰，毕礼明，杜浩昌 . 中医古文献对慢性肾衰竭病名的认识［J］. 中国中医急症， 2010 ， 19 （ 6 ）： 1011 - 1012 .

王洋，高继宁，张敏继 . 中医药治疗慢性肾衰竭研究进展［J］. 中国民间疗法， 2020 ， 28 （ 1 ）： 93 - 95 .

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Exploring the Use of Bitter Medicinals in Chronic Kidney Disease Based on the Theory of Yin Fire

Extension and Application Strategy of Four Examinations of Traditional Chinese Medicine in Chronic Kidney Disease

Prevention and Treatment of Cardiovascular-Kidney-Metabolic Syndrome with Traditional Chinese Medicine Based on the Core Pathogenesis Evolution of "Constraint，Heat，Deficiency，Stasis，and Toxin"

Association between Yang Deficiency Syndrome and the End-point Events of Diabetic Kidney Disease： A Retrospective Cohort Study

Chinese Herbal Enema Combined with Fumigation as Adjunctive Therapy for 60 Cases of Non-dialysis Chronic Kidney Disease Patients of Stage 3-5 with Spleen-kidney Yang Deficiency and Turbid Toxin Blood Stasis Pattern：A Randomized Controlled Trial

Related Author

YAN Lei

WANG Xinhui

LIANG Ying

YU Renhuan

LIU Zhengxin

SONG Qin

HE Yining

YIN Xiaofan

Related Institution

Xiyuan Hospital，China Academy of Chinese Medical Sciences

Qingdao Municipal Hospital

Affiliated Hospital of Nanjing University of Chinese Medicine，Jiangsu Province Hospital of Chinese Medicine

Dongzhimen Hospital，Beijing University of Chinese Medicine

Xi'an No.1 Hospital

Address：No.16, Nanxiao street, Dongzhimen, Dongcheng District, Beijing Postal code：100700
Tel：010-64035632 Email：jtcmcn@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19 京公网安备11010102007558号
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰